A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)

被引：0
|
作者：
Choueiri, T. K. [1 ]
Escudier, B. [2 ]
Powles, T. [3 ]
Cella, D. [4 ]
Lee, Y. [5 ]
Laird, D. A. [5 ]
Scheffold, C. [5 ]
Motzer, R. J. [6 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Queen Mary Univ, Barts Canc Inst, London, England
[4] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Exelixis Inc, San Francisco, CA USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard J.
    Donskov, Frede
    Grunwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoffski, Patrick
    Szczylik, Cezary
    Peltola, Katriina Johanna
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas O.
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Schmidinger, M.
    Tannir, N. M.
    Powles, T.
    Escudier, B. J.
    Donskov, F.
    Gruenwald, V
    Sternberg, C. N.
    Schoffski, P.
    Szczylik, C.
    Peltola, K. J.
    Nosov, D.
    Melichar, B.
    Clary, D. O.
    Scheffold, C.
    Motzer, R. J.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 200
  • [23] Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Bergmann, L.
    Donskov, F.
    Motzer, R. J.
    Voog, E.
    Hovey, E. J.
    Gruellich, C.
    Nott, L. M.
    Cuff, K. E.
    Gil, T.
    Jensen, N., V
    Chevreau, C.
    Negrier, S.
    Depenbusch, R.
    Cornelio, I
    Champsaur, A.
    Escudier, B. J.
    Pal, S. K.
    Powles, T.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 201
  • [24] Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
    Cella, David
    Escudier, Bernard
    Tannir, Nizar M.
    Powles, Thomas
    Donskov, Frede
    Peltola, Katriina
    Schmidinger, Manuela
    Heng, Daniel Y. C.
    Mainwaring, Paul N.
    Hammers, Hans J.
    Lee, Jae Lyun
    Roth, Bruce J.
    Marteau, Florence
    Williams, Paul
    Baer, John
    Mangeshkar, Milan
    Scheffold, Christian
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 757 - +
  • [25] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [26] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Thomas Powles
    Robert J. Motzer
    Bernard Escudier
    Sumanta Pal
    Christian Kollmannsberger
    Joanna Pikiel
    Howard Gurney
    Sun Young Rha
    Se Hoon Park
    Poul F. Geertsen
    Marine Gross-Goupil
    Enrique Grande
    Cristina Suarez
    David W. Markby
    Alan Arroyo
    Mark Dean
    Toni K. Choueiri
    Daniel George
    British Journal of Cancer, 2018, 119 : 663 - 669
  • [27] Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Tannir, N.
    Powles, T.
    Motzer, R. J.
    Rolland, F.
    Gravis, G.
    Staehler, M.
    Rink, M.
    Retz, M.
    Csoszi, T.
    McCaffrey, J.
    De Giorgi, U.
    Caserta, C.
    Cheporov, S.
    Esteban Gonzalez, E.
    Duran, I.
    Larkin, J. G.
    Berg, W.
    Clary, D.
    Escudier, B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Heather A. Wakelee
    Scott Gettinger
    Jeffrey Engelman
    Pasi A. Jänne
    Howard West
    Deepa S. Subramaniam
    Joseph Leach
    Michael Wax
    Yifah Yaron
    Dale R. Miles
    Primo N. Lara
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 923 - 932
  • [29] Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
    Ciccarese, Chiara
    Massari, Francesco
    Tortora, Giampaolo
    EUROPEAN UROLOGY, 2016, 69 (05) : 969 - 970
  • [30] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Wakelee, Heather A.
    Gettinger, Scott
    Engelman, Jeffrey
    Janne, Pasi A.
    West, Howard
    Subramaniam, Deepa S.
    Leach, Joseph
    Wax, Michael
    Yaron, Yifah
    Miles, Dale R.
    Lara, Primo N., Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 923 - 932
12345